Ocugen (OCGN) Share-based Compensation (2014 - 2026)
Ocugen (OCGN) reported Share-based Compensation of $3.4 million for Q1 2026, up 80.27% on a YoY basis from $1.9 million in Q1 2025, and up 69.73% quarter-over-quarter from $2.0 million in Q4 2025.
Ocugen (OCGN) Share-based Compensation (2014 - 2026) Analysis & Trends
Ocugen has reported Share-based Compensation for 13 years, with the latest figure at $3.4 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 80.27% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $8.1 million (up 7.5% YoY), and the FY2025 full-year result was $7.7 million, up 3.77% from the prior year.
- Share-based Compensation for Q1 2026 stood at $3.4 million, up from $2.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $3.4 million in Q1 2026, with the low at $741000.0 in Q2 2025.
- Historically, Share-based Compensation has averaged $2.2 million across 5 years, with a median of $2.0 million in 2025.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 296.04% — and 2025, when it slumped 60.96%.
- Ocugen's Share-based Compensation stood at $2.7 million in 2022, then sank by 35.46% to $1.7 million in 2023, then gained by 8.94% to $1.9 million in 2024, then gained by 6.72% to $2.0 million in 2025, then jumped by 69.73% to $3.4 million in 2026.
- The last three Share-based Compensation figures came in at $3.4 million (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | 3.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.40 Mn |
| Mar 31, 2026 | 3.40 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 741,000.00 |
| Jun 30, 2025 | 741,000.00 |
| Mar 31, 2025 | 1.89 Mn |
| Mar 31, 2025 | 1.89 Mn |
| Dec 31, 2024 | 1.88 Mn |
| Dec 31, 2024 | 1.88 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Dec 31, 2023 | 1.72 Mn |
| Dec 31, 2023 | 1.72 Mn |